The net clinical benefit (NCB) of anticoagulation use in patients with atrial fibrillation (AF) appears to decrease with advancing age, and this decline can be attributed to competing mortality risk, as shown in a study.
Evolocumab treatment over 2.3 years does not seem to benefit atherosclerotic patients without multiple clinical risk factors or high genetic risk, and these individuals also have a low event rate. However, those with high genetic risk, irrespective of clinical risk, have a high event rate and receive large relative and absolute benefit from this therapy, thus alleviating such risk, according to a study presented at the 2019 Scientific Sessions of the American Heart Association.
High levels of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide can help identify patients at risk of adverse cardiovascular events, according to a study presented at the 2019 Scientific Sessions of the American Heart Association (AHA 2019).
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.